{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Number of participants who experience grade III or IV acute GVHD between Day 90 and Day 180. Only participants who are able to stop prophylactic tacrolimus at Day 90 are evaluable.","groups":[{"description":"Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.\n\nFludarabine: Days -6 through -2: 30 mg/m\\^2 IV daily\n\nCyclophosphamide: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily\n\nTotal body irradiation: Day -1: 200 cGy in a single fraction\n\nTacrolimus: Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.\n\nMycophenolate mofetil: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)","id":"OG000","title":"PBSCT D90"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Of the 57 patients in the D90 cohort, 33 stopped tactolimus early as planned.","reportingStatus":"POSTED","timeFrame":"Between Day 90 and Day 180","title":"Number of Participants With Grades III-IV Acute GVHD, Days 90-180 (D90)","type":"SECONDARY","unitOfMeasure":"Participants"}